The ever-increasing prevalence of noncommunicable diseases (NCDs) represents a major
public health burden worldwide. The most common form of NCD is metabolic diseases …

Metabolic associated fatty liver disease (MAFLD) ranks among the most prevalent chronic
liver conditions globally. At present, the mechanism of MAFLD has not been fully elucidated …

Nonalcoholic steatohepatitis (NASH), a common clinical disease, is becoming a leading
cause of hepatocellular carcinoma (HCC). Dual specificity phosphatase 22 (DUSP22, also …

Nonalcoholic fatty liver disease (NAFLD) encompasses a disease continuum from simple
steatosis to nonalcoholic steatohepatitis (NASH). However, there are currently no approved …

Underestimation of the complexity of pathogenesis in nonalcoholic steatohepatitis (NASH)
significantly encumbers development of new drugs and targeted therapy strategies. Inactive …

Background and aims The functions of liver fatty acid binding protein 1 (FABP1) in the
regulation of nonalcoholic fatty liver disease (NAFLD) have been previously established …

Currently potential preclinical drugs for the treatment of nonalcoholic steatohepatitis (NASH)
and NASH-related pathopoiesis have failed to achieve expected therapeutic efficacy due to …

Nonalcoholic steatohepatitis (NASH) is a leading cause for chronic liver diseases. Current
therapeutic options are limited due to an incomplete mechanistic understanding of how …

F-box only protein 2 exacerbates non-alcoholic fatty liver disease by targeting the hydroxyl
CoA dehydrogenase alpha subunit - PMC Back to Top Skip to main content NIH NLM Logo …

LIM domain only 7 negatively controls nonalcoholic steatohep... : Hepatology LIM domain
only 7 negatively controls nonalcoholic steatohepatitis in the setting of hyperlipidemia …